BRPI0713338A2 - formulaÇÕes galÊnicas de compostos orgÂnicos - Google Patents

formulaÇÕes galÊnicas de compostos orgÂnicos Download PDF

Info

Publication number
BRPI0713338A2
BRPI0713338A2 BRPI0713338-3A BRPI0713338A BRPI0713338A2 BR PI0713338 A2 BRPI0713338 A2 BR PI0713338A2 BR PI0713338 A BRPI0713338 A BR PI0713338A BR PI0713338 A2 BRPI0713338 A2 BR PI0713338A2
Authority
BR
Brazil
Prior art keywords
organic compounds
galenic formulations
methoxy
methyl
combinations
Prior art date
Application number
BRPI0713338-3A
Other languages
English (en)
Inventor
Willmann Matthias
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36803824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0713338(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0713338A2 publication Critical patent/BRPI0713338A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAÇÕES GALÊNICAS DE COMPOSTOS ORGÂNICOS. A presente invenção refere-se a uma forma de dosagem oral sólida compreendendo uma quantidade terapeuticamente eficaz de hemifumarato de (2-carbamoil-2-metil-propil)-amida de ácido (2S,4S,5S,7S)-5-amino-4-hidróxi-2-isopropil-7-[4-metóxi-3-(3-metóxi-p ropóxi)-benzil]-8-metil-nonanóico ou um sal farmaceuticamente aceitável do mesmo, uma quantidade terapeuticamente eficaz de HCTZ e uma carga hidrofílica selecionada do grupo, um carboidrato ou combinações dos mesmos, por exemplo, açúcares, álcoois de açúcar e amidos ou combinações dos mesmos.
BRPI0713338-3A 2006-06-23 2007-06-21 formulaÇÕes galÊnicas de compostos orgÂnicos BRPI0713338A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612540.5 2006-06-23
GBGB0612540.5A GB0612540D0 (en) 2006-06-23 2006-06-23 Galenical formulations of organic compounds
PCT/EP2007/005476 WO2007147596A1 (en) 2006-06-23 2007-06-21 Galenical formulations of aliskiren and hydrochlorothiazide

Publications (1)

Publication Number Publication Date
BRPI0713338A2 true BRPI0713338A2 (pt) 2012-03-06

Family

ID=36803824

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713338-3A BRPI0713338A2 (pt) 2006-06-23 2007-06-21 formulaÇÕes galÊnicas de compostos orgÂnicos

Country Status (26)

Country Link
US (1) US8618172B2 (pt)
EP (3) EP2311439A1 (pt)
JP (1) JP5362556B2 (pt)
KR (1) KR101442272B1 (pt)
CN (1) CN101472566A (pt)
AR (1) AR061565A1 (pt)
AU (1) AU2007263261B2 (pt)
BR (1) BRPI0713338A2 (pt)
CA (1) CA2654872A1 (pt)
CL (1) CL2007001837A1 (pt)
EC (1) ECSP088986A (pt)
ES (1) ES2704979T3 (pt)
GB (1) GB0612540D0 (pt)
GT (1) GT200800297A (pt)
IL (1) IL195425A (pt)
MA (1) MA30527B1 (pt)
MX (1) MX2008016533A (pt)
MY (1) MY146779A (pt)
NO (1) NO20090262L (pt)
NZ (1) NZ572937A (pt)
PE (2) PE20120990A1 (pt)
RU (1) RU2491058C2 (pt)
TN (1) TNSN08528A1 (pt)
TW (1) TWI457137B (pt)
WO (1) WO2007147596A1 (pt)
ZA (1) ZA200809773B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091203A1 (es) * 2007-09-28 2009-09-11 Novartis Ag Composiciones farmaceuticas que comprende alisquireno o una sal farmaceuticamente aceptable del mismo
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
JP2010031006A (ja) * 2008-07-17 2010-02-12 Novartis Ag 有機化合物の使用
ES2365429B1 (es) 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
PL2968182T3 (pl) * 2013-03-15 2018-10-31 SpecGx, LLC Zniechęcająca do nadużywania stała postać dawkowania dla natychmiastowego uwalniania z funkcjonalnym rowkiem

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6010719A (en) 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
BR0310084A (pt) * 2002-05-17 2005-02-15 Novartis Ag Composição farmacêutica compreendendo um inibidor de renina, um bloqueador de canal de cálcio e um diurético
BG65538B1 (bg) * 2002-07-05 2008-11-28 "Софарма" Ад Лекарствена форма на силимарин и метод за нейнотополучаване
WO2005077418A1 (en) * 2004-02-17 2005-08-25 Novartis Ag Combination of renin inhibitor and diuretics
PE20142101A1 (es) 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
ATE493973T1 (de) * 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006041763A1 (en) * 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
US8367105B2 (en) * 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
CN101166523A (zh) * 2005-04-27 2008-04-23 诺瓦提斯公司 治疗动脉粥样硬化的方法
RU2008119687A (ru) * 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений

Also Published As

Publication number Publication date
GB0612540D0 (en) 2006-08-02
US8618172B2 (en) 2013-12-31
CL2007001837A1 (es) 2008-06-13
PE20120990A1 (es) 2012-08-16
KR101442272B1 (ko) 2014-09-22
PE20080373A1 (es) 2008-06-06
TWI457137B (zh) 2014-10-21
MA30527B1 (fr) 2009-06-01
MX2008016533A (es) 2009-01-19
EP2311439A1 (en) 2011-04-20
ES2704979T3 (es) 2019-03-21
AR061565A1 (es) 2008-09-03
NZ572937A (en) 2011-11-25
US20090203679A1 (en) 2009-08-13
RU2009101971A (ru) 2010-07-27
EP2034968B1 (en) 2018-10-31
TW200808358A (en) 2008-02-16
ECSP088986A (es) 2009-01-30
KR20090021353A (ko) 2009-03-03
CN101472566A (zh) 2009-07-01
GT200800297A (es) 2009-03-09
JP5362556B2 (ja) 2013-12-11
TNSN08528A1 (en) 2010-04-14
IL195425A0 (en) 2009-08-03
JP2009541239A (ja) 2009-11-26
NO20090262L (no) 2009-01-19
AU2007263261A1 (en) 2007-12-27
IL195425A (en) 2014-01-30
AU2007263261B2 (en) 2011-07-14
CA2654872A1 (en) 2007-12-27
ZA200809773B (en) 2009-11-25
RU2491058C2 (ru) 2013-08-27
WO2007147596A1 (en) 2007-12-27
EP3391878A1 (en) 2018-10-24
MY146779A (en) 2012-09-28
EP2034968A1 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
BRPI0713338A2 (pt) formulaÇÕes galÊnicas de compostos orgÂnicos
EA200802444A1 (ru) Стабилизированные фармацевтические композиции, содержащие фезотеродин
SG161256A1 (en) Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
BRPI1014783A2 (pt) formulações farmacêuticas e métodos para tratar infecções do trato respiratório
BRPI0906104A2 (pt) "derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade "terapeuticamente eficaz do derivado de ácido nuclêico peptídico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido nuclêico peptídico,método de utilização do derivado de ácido nuclêico peptídico e composto"
BRPI0605214A (pt) composição farmacêutica orodispersável para administração por via mucosa oral ou sublingual de agomelatina
WO2010038237A3 (en) Compositions exhibiting delayed transit through the gastrointestinal tract
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
AR084781A1 (es) Composiciones que comprenden y metodos que utilizan inhibidores de los cotransportadores de sodio-glucosa 1 y 2
AR061668A1 (es) Jarabes antihistaminicos, estables al almacenamiento, sin azucar
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
NO20083555L (no) Sammensetninger omfattende desmopressin
CY1115516T1 (el) Φαρμακευτικη συνθεση που περιεχει ενα συνδυασμο ενος μη στεροειδικου αντιφλεγμονωδους παραγοντα και ενος αντισπασμωδικου παραγοντα
EA200801634A1 (ru) Твердая фармацевтическая композиция, содержащая ирбесартан
EP2801359A3 (en) The use of nicotine for the treatment of sepsis in humans caused by antibiotic
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
EA201100104A1 (ru) Фармацевтическая композиция, содержащая статин
MA32719B1 (fr) Formulations galeniques de composes organiques
GT201000064A (es) Formulaciones galénicas de alisquireno
WO2010029093A3 (en) Compositions for percutaneous administration

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]